乌鸦传媒

The antipsychotic brexpiprazole (Rexulti) was effective for . In new data presented at the 2018 Psych Congress in San Diego, the treatment showed improvements in PANSS total score and had a 47% response rate in patients.

In other news from the meeting, research showed the -- a dual-acting dopamine and norepinephrine reuptake inhibitor -- was effective for the treatment of binge eating disorders (BEDs).

The in the phase III DAYBREAK trial, the maker Lundbeck announced. Compared with other treatments already on the market for resistant schizophrenia, risperidone and olanzapine, the investigational treatment failed to show statistical superiority, which was the trial's primary endpoint. (PharmaTimes)

As many as 80% of kids tested for fibromyalgia were originally , according to new data from EpicGenetics. (AP)

A simple, noninvasive eye test may be the future for diagnosing early Alzheimer's disease, according to several new studies presented at the the 2018 American Academy of Ophthalmology (AAO) meeting in Chicago. Catch up on all of 乌鸦传媒's AAO coverage here. (ScienceDaily)

An adult ADHD treatment, , succeeded in a clinical trial, the maker VAYA Pharma announced at the 2018 American Academy of Child and Adolescent Psychiatry meeting in Seattle. The capsule treatment combines phosphatidylserine attached to omega-3 enriched with eicosapentaenoic acid.

A pair of FDA advisory committees will meet on Thursday to review the safety and efficacy of the first possible opioid for depression -- Alkermes' oral treatment ALKS 5461 (buprenorphine/samidorphan) for major depressive disorder (MDD). Check back for 乌鸦传媒's coverage of the results.

The U.S. Department of Defense awarded a $3 million grant to a research group from the University of California San Diego to study . "Veterans and active duty service members may be at increased risk for BED due to conditions during military service that encourage eating food quickly with increased stress and pressure and periods of deprivation," said principal investigator Kerri Boutelle, PhD, in a statement.

Comment